SLV-154 Treatment of Advanced Cancers

ClinicalTrials.gov ID: NCT06771219

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT06771219. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Dose-Escalation/Expansion Study of SLV-154 in Subjects With Advanced Cancers

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 1 study comprising a Phase 1a dose-escalation portion and a Phase 1b expansion portion evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with advanced solid tumors.

Study identification

NCT ID: NCT06771219
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Solve Therapeutics; Industry
Enrollment: 250 participants

Conditions and interventions

Conditions

Interventions

SLV-154 Drug

Drug

Eligibility (public fields only)

Age range: 12 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 14, 2025 (Actual)
Primary completion: Aug 2027 (Estimated)
Completion: Nov 2027 (Estimated)
Last update posted: Sep 22, 2026

2025 – 2027

United States locations

U.S. sites: 12
U.S. states: 8
U.S. cities: 11

Facility	City	State	ZIP	Site status
Hoag Memorial Hospital Presbyterian	Newport Beach	California	92663	Recruiting
Washington University	St Louis	Missouri	63110	Recruiting
Astera Cancer Care	East Brunswick	New Jersey	08816	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
University Hospitals Cleveland Medical Center	Cleveland	Ohio	44106	Recruiting
The James Outpatient Care West Center	Columbus	Ohio	43210	Recruiting
Fox Chase Cancer Center	Philadelphia	Pennsylvania	19111	Recruiting
MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
Oncology Consultants	Houston	Texas	77030	Recruiting
Mays Cancer Center; University of Texas Health San Antonio	San Antonio	Texas	78229	Recruiting
University of Washington / Fred Hutchinson Cancer Center	Seattle	Washington	98109	Recruiting
Northwest Medical Specialties, PLLC	Tacoma	Washington	98405	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06771219, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 22, 2026 · Synced Nov 13, 2026